CeNeRx BioPharma initiates human trials of RIMA antidepressant
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced the initiation of human clinical trials of TyrimaTM, CeNeRx’ s new drug candidate with a triple mechanism of action for the treatment of depression and anxiety. Tyrima (formerly CX157) is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMA. The Phase I safety trials began this month following a successful review of the Investigational New Drug (IND) application for Tyrima by the U.S. Food and Drug Administration.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.